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We conducted a prevalence study of mutations in Plasmodium falciparum that are associated with antifolate
resistance in Blantyre, Malawi. The dihydrofolate reductase 164-Leu mutation, which confers resistance to
both pyrimethamine and chlorproguanil, was found in 4.7% of the samples. Previously unreported mutations
in dihydropteroate synthase were also found.
Sulfadoxine-pyrimethamine (SP) is the first-line antimalarial
in much of Africa. Resistance to SP in Plasmodium falciparum
is increasing and is conferred by mutations in dihydrofolate
reductase (DHFR) and dihydropteroate synthase (DHPS). A
combination of five mutations (“quintuple mutant”: DHFR-51,
-59, and -108 and DHPS-437 and -540) strongly predicts clin-
ical outcome (10, 13). Mutations in DHFR-164, DHPS-581,
and DHPS-613 develop later and are associated with increased
SP resistance (14).
One proposed alternative to SP is chlorproguanil-dapsone
(Lapdap). Both chlorproguanil and pyrimethamine target
DHFR, and changes at codon 164 confer resistance to both
drugs (7). This cross-resistance might limit the usefulness of
Lapdap in areas where SP has been used heavily (11). Cur-
rently in Africa, DHFR-164 mutations are rare. Nevertheless,
this mutation should be monitored where Lapdap is being
considered as a candidate therapy.
In Malawi, SP has been the first-line agent for malaria since
1993. The quintuple mutation is widespread: 78% of samples
contained the quintuplet mutation in the Salima district in
2001 (5). However, subsequent mutations (DHPS-613, DHPS-
581, and DHFR-164) have not been previously reported. The
purpose of this study is to determine the prevalence of muta-
tions in DHFR and DHPS in Blantyre, Malawi.
Clinical samples of Plasmodium falciparum were acquired
from pregnant women at Queen Elizabeth Hospital (Blantyre,
Malawi) who were enrolled in a study investigating mother-to-
child transmission of human immunodeficiency virus (12). Ve-
nous blood was taken at enrollment and frozen at 80°C.
Malaria was screened for using thick-blood-smear microscopy.
A random sample of the Plasmodium falciparum-positive spec-
imens was included in this study. Twenty-two samples were
transferred to filter paper and processed as previously de-
scribed (1). Sixty-eight additional samples were shipped frozen
to the University of North Carolina at Chapel Hill (UNC-
Chapel Hill), where DNA was extracted using the Qiamp DNA
minikit (Qiagen). The samples for this study were collected
between March 2001 and May 2003. In this subgroup, 15.7%
report taking SP within the last 2 weeks while 85.4% report
taking SP at some point during their pregnancy. No one re-
ported using Lapdap. Institutional review boards at UNC-
Chapel Hill and the University of Malawi College of Medicine
approved all research.
All samples were genotyped for codons 51, 59, and 108 in the
DHFR gene and codons 437, 540, 581, and 613 in the DHPS
gene, as previously described (1). The DHFR/DHPS genotypes
for five of the blood spot samples were reported previously (1).
The samples were genotyped at DHFR-164 using a new
real-time PCR assay with minor groove binder (MGB) probes
(Table 1). The primers and probes were synthesized by MWG
Biotech (High Point, NC) and Applied Biosystems (ABI), re-
spectively. PCRs were carried out in duplicate in 25 l reaction
mixtures containing 12.5 l Universal PCR Master Mix (ABI),
2 l DNA, forward primer at 300 nM, reverse primer at 500
nM, and both probes at 200 nM. All reactions were run on an
ABI PRISM 7000 (ABI); reaction mixtures were initially de-
natured at 95°C for 10 min and cycled 45 times, with each cycle
consisting of 92°C for 14 s and 60°C for 60 s. The results were
analyzed as previously described (1). A sample was considered
mixed if there was an increase in the signal for both the wild-
type and mutant probes.
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To validate this assay, genomic DNA (Dd2, HB3, W2,
FCR3, K1, and VI/S from the Malaria Reagent Repository
Resource [http://www.malaria.mr4.org/]) was genotyped for
DHFR-164. The assay correctly identified VI/S as mutant and
the rest as wild type. Clinical samples were sequenced for
further validation. The amplified product from the real-time
reaction was purified using CentriSpin-10 columns (Princeton
Separations) and then sequenced as previously described (1).
To check for contamination, samples with the DHFR-164 mu-
tation were genotyped for PFCRT-76, which is mutant in VI/S
but wild type in Malawian samples (9, 17).
Eighty-seven out of the 90 samples were genotyped success-
fully for all codons. Of these samples, 93.2% contained the
quintuple mutation (Fig. 1). One sample (1.1%) contained a
DHPS-613 mutant component, while three different samples
(3.4%) contained a DHPS-581 mutant component. These mu-
tations were only observed in mixed infections.
Genotyping for DHFR-164 was successful for 85 out of 90
samples. Four samples contained the DHFR-164-Leu muta-
tion, which results in a prevalence of 4.7% (95% confidence
interval: 0, 9.2%). One sample contained only the mutant ge-
notype, while the rest contained a mixture of wild-type and
mutant genotypes. The genotypes of the fully mutant sample
and two wild-type samples were confirmed with sequencing.
The four samples with the DHFR-164 mutation also contained
the quintuple mutation but were wild type at DHPS-581 and
DHPS-613. These four samples were wild type at PFCRT-76,
which suggests the DHFR-164 mutation was not due to con-
tamination.
Malawi was one of the first African countries to adopt SP as
the first-line agent against Plasmodium falciparum malaria.
This is the first report of the DHFR-164, DHPS-581, and
DHPS-613 mutations in clinical samples from Malawi. The
presence of these mutations suggests SP resistance may be
increasing. Mutations in DHFR-164 and DHPS-581 and
DHPS-613 have been associated with high-level SP resistance
in Southeast Asia and Latin America (3, 4, 14). The observa-
tion of these mutations in Malawi suggests that P. falciparum
strains with high-level SP resistance may be occurring in Af-
rica, too. The presence of the DHFR-164-Leu mutation is
troubling because it confers cross-resistance to Lapdap. In
Africa, the DHFR-164 mutation has rarely been found: previ-
ous reports of this mutation were from travelers and people
treated with Lapdap, and it was also found as a rare compo-
nent of samples (6, 8, 15). In contrast, we report the DHFR-
164 mutation as a major component of samples in African
women who report not taking Lapdap.
Our screening for DHFR and DHPS mutations was re-
stricted to pregnant women in Blantyre with previous SP ex-
posure, and therefore the prevalence of these mutations in the
general population is uncertain. In fact, Lapdap has been ef-
ficacious in recent clinical trials in children in Blantyre (2, 16),
suggesting that the DHFR-164 mutation remains rare. Never-
theless, continued surveillance for these mutations is needed,
as is confirmation that these mutations are associated with high
levels of clinical SP and Lapdap resistance. New technologies
for SNP detection, such as real-time PCR, enable rapid low-
cost screening of a large number of samples and can be em-
ployed for the monitoring of parasite mutations associated
with drug resistance.
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